Live feed07:00:00·1474dPRReleasevia QuantisnowAldeyra Therapeutics Achieves Primary Endpoint in Phase 3 TRANQUILITY‑2 Trial in Dry Eye Disease and Intends to Submit New Drug Application for Symptoms and Three Sign Endpoints of Dry Eye DiseaseByQuantisnow·Wall Street's wire, on your screen.ALDX· Aldeyra Therapeutics Inc.Health Care
